Announcements Trials
Browse Landscape

Phase

Phase 1 8Phase 2 5Phase EARLY_PHASE1 1Phase 3 1Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1

Conditions

Ovarian Neoplasms 12Small Cell Lung Carcinoma 8Carcinoma, Ovarian Epithelial 5Uterine Cervical Neoplasms 4Neoplasms 4Neuroblastoma 3Lung Neoplasms 3Leukemia, Myeloid, Acute 3Leukemia 3Fallopian Tube Neoplasms 3Unspecified Adult Solid Tumor, Protocol Specific 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasm Metastasis 2Myelodysplastic Syndromes 2Leukemia, Myelomonocytic, Chronic 2Anemia, Refractory, with Excess of Blasts 2Thrombocytopenia 1Solid Tumors 1Sarcoma, Ewing 1Sarcoma, Clear Cell 1SCLC, Extensive Stage 1Recurrence 1Radiation Injuries 1Primary Myelofibrosis 1Polycythemia Vera 1Peritoneal Neoplasms 1Myoepithelioma 1Myeloproliferative Disorders 1Multiple Myeloma 1Liposarcoma, Myxoid 1

Interventions

Dexamethasone 33Cyclophosphamide 29venetoclax 18fludarabine 18Lenalidomide 16Bortezomib 16Cytarabine 13pembrolizumab 12Calcium Dobesilate 12Carboplatin 11fludarabine phosphate 10Rituximab 10pomalidomide 9Gemcitabine 9Nivolumab 8Azacitidine 7daratumumab 6carfilzomib 6blinatumomab 6Decitabine 6Bendamustine Hydrochloride 6selinexor 5obinutuzumab 5ibrutinib 5Vincristine 5Temozolomide 5Methotrexate 5Etoposide 5Cisplatin 5tafasitamab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Recurrence × Topotecan × Clear all
NCT02100007 2017-10-02

ME-344 Given in Combination With Hycamtin® in Patients With Solid Tumors

MEI Pharma, Inc.

Phase 1/2 Terminated
46 enrolled 17 charts
GynecologicThoracic

Neoplasm Metastasis, Ovarian Neoplasms, Recurrence, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡